KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $268000.0.

  • Arbutus Biopharma's Other Operating Expenses fell 2209.3% to $268000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 17879.42%. This contributed to the annual value of $2.6 million for FY2024, which is 370434.78% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Other Operating Expenses of $268000.0 as of Q3 2025, which was down 2209.3% from $225000.0 recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Other Operating Expenses ranged from a high of $1.9 million in Q4 2024 and a low of -$636000.0 during Q2 2023
  • Moreover, its 5-year median value for Other Operating Expenses was $225000.0 (2025), whereas its average is $329736.8.
  • Per our database at Business Quant, Arbutus Biopharma's Other Operating Expenses surged by 73367.88% in 2022 and then plummeted by 40576.92% in 2023.
  • Over the past 5 years, Arbutus Biopharma's Other Operating Expenses (Quarter) stood at $193000.0 in 2021, then surged by 733.68% to $1.6 million in 2022, then crashed by 85.89% to $227000.0 in 2023, then skyrocketed by 732.6% to $1.9 million in 2024, then tumbled by 85.82% to $268000.0 in 2025.
  • Its Other Operating Expenses was $268000.0 in Q3 2025, compared to $225000.0 in Q2 2025 and $299000.0 in Q1 2025.